Advertisement

Left atrial appendage closure devices: A reasonable therapeutic alternative

  • Vivek Y. Reddy
    Correspondence
    Address reprint requests and correspondence: Dr Vivek Y. Reddy, Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, Box 1030, New York, NY 10029.
    Affiliations
    Icahn School of Medicine at Mount Sinai, New York, New York
    Search for articles by this author
Published:October 10, 2017DOI:https://doi.org/10.1016/j.hrthm.2017.10.006
      Preventing stroke is arguably the most important goal in the management of atrial fibrillation (AF). For decades, oral anticoagulation (OAC)—initially with warfarin, and more recently, with nonwarfarin oral anticoagulants (NOACs)—has been the therapeutic mainstay for stroke prophylaxis. However, many patients are poor candidates for lifelong OAC therapy. This clinical need prompted the emergence of the therapeutic alternative, left atrial appendage closure (LAAC). Herein, I discuss the clinical evidence supporting LAAC’s role as a reasonable stroke-prevention alternative.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Heart Rhythm
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Reddy V.Y.
        • Sievert H.
        • Halperin J.
        • Doshi S.K.
        • Buchbinder M.
        • Neuzil P.
        • Huber K.
        • Whisenant B.
        • Kar S.
        • Swarup V.
        • Gordon N.
        • Holmes D.
        • PROTECT-AF Steering Committee and Investigators
        Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial.
        JAMA. 2014; 312 ([correction published in JAMA 2015;313(10):1061]): 1988-1998
        • Reddy V.Y.
        • Holmes D.
        • Doshi S.K.
        • Neuzil P.
        • Kar S.
        The safety of percutaneous left atrial appendage closure: results from PROTECT-AF and the continued access registry.
        Circulation. 2011; 123: 417-424
        • Reddy V.Y.
        • Gibson D.N.
        • Kar S.
        • O’Neill W.
        • Doshi S.K.
        • Horton R.P.
        • Buchbinder M.
        • Gordon N.T.
        • Holmes D.R.
        Post-FDA approval, initial US clinical experience with Watchman Left Atrial Appendage Closure for stroke prevention in atrial fibrillation.
        J Am Coll Cardiol. 2017; 69: 253-261
        • Holmes Jr., D.R.
        • Kar S.
        • Price M.J.
        • Whisenant B.
        • Sievert H.
        • Doshi S.K.
        • Huber K.
        • Reddy V.Y.
        Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.
        J Am Coll Cardiol. 2014; 64: 1-12
      1. Circulatory System Devices Panel: Watchman Left Atrial Appendage Closure Therapy Sponsor Presentation. 2014 FDA Circulatory System Devices Panel. Available at: https://wayback.archive-it.org/7993/20170114045413/http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/CirculatorySystemDevicesPanel/UCM421983.pdf.

        • Holmes Jr., D.R.
        • Doshi S.K.
        • Kar S.
        • Price M.J.
        • Sanchez J.M.
        • Sievert H.
        • Valderrabano M.
        • Reddy V.Y.
        Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis.
        J Am Coll Cardiol. 2015; 65: 2614-2623
        • Boersma L.V.
        • Ince H.
        • Kische S.
        • et al.
        • EWOLUTION Investigators
        Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial.
        Heart Rhythm. 2017; 14: 1302-1308
        • Tzikas A.
        • Shakir S.
        • Gafoor S.
        • et al.
        Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER cardiac plug.
        EuroIntervention. 2016; 11: 1170-1179
      2. Friedman DJ, Piccini JP, Wang T, et al. Comparative effectiveness of left atrial appendage occlusion among patients with atrial fibrillation undergoing concomitant cardiac surgery: a report from the Society of Thoracic Surgeons adult cardiac surgery database. Presented at: American College of Cardiology 66th Annual Scientific Session & Expo (ACC.17); Washington, DC, March 19, 2017. Available at: http://www.clinicaltrialresults.org/Slides/ACC2017/LAAO_CE_Friedman.pdf; Accessed October 16, 2017.

        • Held C.
        • Hylek E.M.
        • Alexander J.H.
        • et al.
        Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial.
        Eur Heart J. 2015; 36: 1264-1272
        • Landmesser U.
        • Schmidt B.
        • Nielsen-Kudsk J.E.
        • et al.
        Left atrial appendage occlusion with the AMPLATZER Amulet device: Periprocedural and early clinical/echocardiographic data from a global prospective observational study.
        Eurointervention. 2017; 13: 867-876
        • Viles-Gonzalez J.F.
        • Kar S.
        • Douglas P.
        • Dukkipati S.
        • Feldman T.
        • Horton R.
        • Holmes D.
        • Reddy V.Y.
        The clinical impact of incomplete left atrial appendage closure with the Watchman device in patients with atrial fibrillation: a PROTECT AF substudy.
        J Am Coll Cardiol. 2012; 59: 923-929
        • Reddy V.Y.
        • Akehurst R.L.
        • Armstrong S.O.
        • Amorosi S.L.
        • Beard S.M.
        • Holmes Jr., D.R.
        Time to cost-effectiveness following stroke reduction strategies in AF: warfarin versus NOACs versus LAAC closure.
        J Am Coll Cardiol. 2015; 66: 2728-2739